anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Certain CYP3A Substrates

LORBRENA is a moderate CYP3A inducer. Concomitant use of LORBRENA decreases the concentration of CYP3A substrates [see Clinical Pharmacology (12.3)], which may reduce the efficacy of these substrates. Avoid concomitant use of LORBRENA with certain CYP3A substrates, for which minimal concentration changes may lead to serious therapeutic failures. If concomitant use is unavoidable, increase the CYP3A substrate dosage in accordance with approved product labeling. 

Certain P-glycoprotein (P-gp) Substrates

LORBRENA is a moderate P-gp inducer. Concomitant use of LORBRENA decreases the concentration of P-gp substrates [see Clinical Pharmacology (12.3)], which may reduce the efficacy of these substrates. Avoid concomitant use of LORBRENA with certain P-gp substrates for which minimal concentration changes may lead to serious therapeutic failures. If concomitant use is unavoidable, increase the P-gp substrate dosage in accordance with approved product labeling.
Sleep disturbance is common among women with breast cancer and is associated with greater symptom distress and poorer outcomes. Yet, for the unique subgroup of young women with breast cancer (YWBC), there is limited information on sleep. To address the gap in our understanding of sleep health in YWBC, we explored their perspective on sleep quality, sleep changes over time, contributing factors, and any strategies used to promote sleep. As part of an explanatory sequential mixed method study, we recruited a sub-sample of 35 YWBC (≤ 50 years of age at the time of diagnosis) from the larger quantitative study phase. These participants were within the first 5 years since diagnosis and completed primary and systemic adjuvant therapy. We conducted virtual semi-structured interviews, transcribed them verbatim, and analyzed data with an interpretive description approach. YWBC experience difficulty falling asleep, waking up at night, and not feeling refreshed in the morning. They attributed interrupted sleep to vasomotor symptoms, anxiety/worry, ruminating thoughts, everyday life stressors, and discomfort. The sleep disturbance was most severe during and immediately after treatment but persisted across the 5 years of survivorship. The participants reported trying pharmacologic and non-pharmacologic strategies to improve the quantity and quality of their sleep. Future research would benefit from longitudinal designs to capture temporal changes in sleep and develop interventions to improve sleep health. Clinically, assessment of sleep health is indicated for YWBC related to the prevalence of disturbed sleep. IMPLICATIONS FOR CANCER SURVIVORS: Early access to sleep assessment and management, ideally before cancer treatment, would be beneficial for young breast cancer survivors. In addition, cancer treatment plans should include physical and psychological symptoms, especially those reported by women in this study: vasomotor symptoms, anxiety and worry, discomfort, and pain.
All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered high-risk, if the reached a partial remission and were IPI 3, 4 or 5 at time of diagnosis of PTLD, if they show stable disease or if they had progressive disease but are not recipients of heart or lung transplants. Patients considered high-risk will receive four more applications of rituximab sc combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113.
PURPOSE:To provide the bath agent composition excellent in the skin moisture- retaining effect and the dryness-improving effect and capable of changing the skin of a man into a non-adhesive and smooth state after the man takes a bath. CONSTITUTION:The bath composition contains (A) a choresteryl ester derivative, e.g. a 8-20C saturated or non-saturated linear or branched fatty acid, especially a monomethyl-branched fatty acid choresteryl ester (e.g. choresteryl isostearate or choresteryl isopalmitate) and (B) an anti-inflammatory agent, e.g. a glycyrrhizic acid derivative, glycyrrhetic acid derivative or azulene derivative in an A:B ratio of 0.1-60wt.%:0.005-20wt.%. The composition can be compounded with an oily component selected from fats and oils, waxes, hydrocarbons, higher fatty acids, higher alcohols, esters, essential oils and silicone oils to enhance the moisture-retaining effect of the composition.
The face-to-face intervention CARE-FAM is a family-based intervention for the diagnostic, early detection and early treatment of mental health issues of children affected by rare diseases, their siblings and their parents. CARE-FAM is a brief low-frequency intervention comprising six to eight sessions per family over a period of six months. Following a preliminary talk, 2 sessions with the parents, 1 session with each affected child and each sibling and 3 sessions with the whole family will take place. This low-frequency approach (sessions every 2 to 3 weeks) allows families to integrate the intervention into their daily life. Upon request, the sessions will take place at the family's home (home-treatment).
The study examines the efficacy of a computer-based training program for individuals with problematic and pathological gambling behavior. The main objective of the study is to investigate the extent to which the online program leads to a significant reduction in pathological gambling. The primary outcome is the Pathological Gambling Adaptation of the Yale-Brown Obsessive Compulsory Scale (PG-YBOCS total score) as a measure of the severity of pathological gambling symptoms. Secondary outcomes are further measures of gambling-related symptoms, such as the South Oaks Gambling Screen (SOGS), as well as rates of depression, measured with the Patient Health Questionnaire - 9 items depression module (PHQ-9), and rates of impulsivity, measured with the impulsivity subscale of the Eysenck's Impulsivity Inventory (I-7). The training is expected to lead to a significant reduction in problematic/pathological gambling behavior (PG-YBOCS) and all secondary outcomes when compared to a control group. The study design is a randomized-controlled trial with one intervention group and one wait-list control group and two assessment times (pre and post). The intervention group receives the download link for the training program directly following the baseline survey and can use the training over a period of 8 weeks, whereas the wait-list control group receives access to the training after completion of the post-survey.
The invention provides a pyranochromene-3-formamide derivative and application thereof in preparing a medicament for preventing and treating sepsis. A series of researches find and prove that the pyranochromene-3-formamide derivative named as a compound Z20 has an obvious protective effect on sepsis. Z20 is applied to an LPS-induced sepsis mouse model, and the survival rate of sepsis mice is obviously improved. In organ damage research of sepsis mice, Z20 is found to slow down the damage of liver, lung and kidney tissues of the sepsis mice, obviously inhibit the expression of inflammatory factors and relieve inflammation outbreak in the sepsis process. The in vivo safety evaluation result shows that Z20 has no obvious toxic or side effect on mice. Therefore, the compound Z20 is a potential novel sepsis prevention and treatment drug, can be used for preventing or treating sepsis inflammation outbreak, and is expected to become a candidate drug for preventing and treating sepsis to carry out deep research and development.
A method is disclosed for detecting the presence of HTLV III infected cells in a medium. The method comprises contacting the medium with monoclonal antibodies against an antigen produced as a result of the infection and detecting the binding of the antibodies to the antigen. The antigen may be a gene product of the HTLV III virus or may be bound to such gene product. On the other hand the antigen may not be a viral gene product by may be produced as a result of the infection and may further be bound to a lymphocyte. The medium may be a human body fluid or a culture medium. A particular embodiment of the present method involves a method for determining the presence of an AIDS virus in a person. The method comprises combining a sample of a body fluid from the person with a monoclonal antibody that binds to an antigen produced as a result of the infection and detecting the binding of the monoclonal antibody to the antigen. The presence of the binding indicates the presence of an AIDS virus infection. Also disclosed are novel monoclonal antibodies, novel compositions of matter, and novel diagnostic kits.
The invention relates to a cyclo-chromo-serine-valine-leucine peptide (Trp-Ser-Val-Val-Leu cyclic peptide) with antifungal and free radical scavenging activities and a preparation method thereof, belonging to the technical field of extraction and preparation of biological products. The cyclo-tryptophan-serine-valine-leucine peptide is a pentadecatomic cyclic pentapeptide which is formed by connecting tryptophan, serine, valine and leucine through an amide bond. This is a novel compound and has not been reported in the literature. The compound of the invention can be obtained by culturing ranunculus japonicus and then extracting and separating. The pure Cyclo-Ser-Val-Leu peptide is white powder, and has half of scavenging concentration (DC) for DPPH free radical  50  ) Comprises the following steps: 1.17mg/mL, and the diameter of the zone of inhibition for Streptococcum albopictus at a concentration of 200. mu.g/mL is 14.62 mm. The compound has the potential of preparing antibacterial drugs and antioxidant and anti-aging health care products.
1398099 Xanthone carboxylic acids SYNTEX (USA) Inc 12 July 1972 [23 Aug 1971] 38515/74 Divided out of 1398096 Heading C2C The invention comprises compounds of the formula wherein one X is H and the other X is a group of formula  wherein R is OH, NH 2 , or mono- or di-(C 1 -C 5 ) alkylamino; and pharmaceutically acceptable, non-toxic esters, amides and salts thereof. They may be obtained by treating a 5- or 7-mereaptoxanthone-2-carboxylic acid with Cl 2  under acidic conditions to give the corresponding 5- or 7- chlorosulphonyl substituted compounds and treating the latter either with an inorganic base other than NH 3  to give the corresponding 5- or 7-sulphoxanthone-2-carboxylic acids; or with NH 3  or a mono- or di-(C 1 -C 5 ) alkylamine to give the corresponding 5- or 7-sulphamoyl, -N-monoalkylsulphamoyl, and -N,N-dialkylsulphamoylxanthone-2-carboxylic acids; and optionally converting any of these products to their corresponding pharmaceutically acceptable, non-toxic esters, amides or salts. Examples are given for the preparation of these compounds. Compounds of the above formula are useful for inhibiting the effects of allergic reactions, also as smooth muscle relaxants and as vasodilators. The compositions containing these compounds optionally together with other pharmaceutical agents, e.g. antibiotics and hormonal agents, may be administered orally, topically, parenterally, or by inhalation and in the form of either solid, liquid or gaseous doses including tablets, suspensions and aerosols.
Systemic lupus erythematosus SLE is an autoimmune disease that affects ∼5.5 per 100,000 individuals worldwide . SLE is characterized by loss of tolerance against nuclear autoantigens, lymphoproliferation, polyclonal autoantibody production, immune complex disease, and multiorgan tissue inﬂammation. Up to 50% of SLE patients develop some degree of renal involvement, with up to 20% progressing to end-stage renal disease, depending on racial background . Lupus nephritis LN is characterized by anti-nuclear Ab production, immune complex deposition, and immune-mediated kidney damage. Development of LN remains a sign of poor prognosis and is a signiﬁcant cause of morbidity and mortality . Because 9 of 10 SLE patients are women, the role of the sex hormones estrogens in this disease is of key interest. Estrogens signal through two receptors: estrogen receptor a ERa and estrogen receptor b ERb. In contrast to estrogen receptor b, ERa is found in female reproductive organs, yet is robustly expressed in kidney, liver, heart, and lungs in males and females,as well as on most immune cells however the kidney is considered the most estrogenic nonreproductive organ. The overwhelming female predominance for SLE begins at puberty and extends to menopause , supporting the concept that estrogens or other reproductive factors stimulate lupus development. This concept is further evidenced by reports of menstrual cycle flares of SLE , disease exacerbations by oral contraceptives or estrogen administration , and induction of lupus by ovulation regimens . Ultraviolet rays has arole in the flarring up SLE. There is evidence that fibroblasts and blood lymphocytes from SLE patients are hypersensitive to the cytotoxic effects of UV light radiation

. RNA and protein synthesis is also affected by UV light 18. A study from 1986 found that people were more likely to menstruate during a new moon, which occurs during the opposite half of the lunar cycle than the full moon . There are different evolutionary theories speculating why the human menstrual cycle length evolved to be so close to the lunar cycle in length. Stories and beliefs connecting the two are also found in various cultures and mythologies . The terms menstruation and menses even come from Latin and Greek words meaning month mensis and moon mene
The invention relates to black powder in southern shaanxi prepared from natural Chinese medicines. The black powder is prepared by the following steps: preparing six traditional Chinese medicines such as radix curcumae, persimmon leaves, pseudo-ginseng, American ginseng, rhizoma nelumbinis and peanut coat; removing impurities, adding water, decocting for 60-120 minutes; filtering and concentrating into paste, drying and crushing into fine powder, and then processing into small granules which are packaged in bags or small bottles, orally taking the black powder to stop bleeding. A part of fine powder is bottled for stopping traumatic bleeding. The black powder in southern shaanxi has effects on nosebleed, hematemesis, hematuria, hemorrhoidal bleeding, and stomach, lung and renal hemorrhage of men and women of all ages, fundus hemorrhage, cerebral hemorrhage bleeding, discharging fresh blood stool, hypermenorrhea of women, dripping with blood, odinopoeia, uterine apoxesis, miscarriage, cesarean section hemorrhage and traumatic bleeding. 2-3 bags of black powder are taken to treat massive haemorrhage; each bag of black powder contains six granules; one bag of black powder is taken for treating little bleeding; the black powder is taken during the bleeding time; the powder is spread on a bleeding part to treat hemorrhoidal bleeding; the wound can be stanched and healed after being bandaged. Thus, the black powder in southern shaanxi has magical effect of internal and external bleeding.
The invention belongs to the technical field of the pharmaceutical technology, and particularly relates to a saxagliptin capsule and a preparation method thereof. The saxagliptin capsule is prepared from, by weight, 5%-99.9% of medicated particles and 0.1%-95% of additional auxiliary materials. The medicated particles include, by weight, 1-30% of saxagliptin hydrochloride and 15-80% of excipient. The additional auxiliary materials include, by weight, 1-20% of lubricant and 0.1-80% of filler. The weight of saxagliptin hydrochloride is counted according to saxagliptin, and the additional auxiliary materials exist in form of powder or particles. The saxagliptin capsule and the preparation method are high in medicine stability and simple in preparation process.
Arm had 2 levels: provider (cluster) level and patient level. Providers, randomly assigned to the intervention arm, refer to VisualDx when they saw a patient who presented with a skin problem. Their patients were assigned to the intervention group and interviewed about the outcomes of their treatment.
They will rinse a solution containing a total of 400 mg caffeine (20 mL, 2% concentration) in the mouth for 20 seconds and try to continue the exercise against increasing resistance until exhaustion. The exercise test will be performed on a bicycle ergometer (Ergometer Exercise Bike SANA 500, Germany) (where the pedaling speed is kept constant at 60 rpm, with an initial load of 50 Watts and a load increase of 25 watts per minute, gradually increasing until the participants become exhausted. To be able to determine the degree of difficulty perceived during the test and The Borg Scale will be used to end the test when the athlete reaches the point of exhaustion.
Attention has been increasingly paid to the "culturally and linguistically diverse (CLD)" communities which typically include dialectal users of English, monolingual and multilingual speakers of minority languages, and bilingual speakers of English and a minority language. However, among these, monolingual speakers of minority languages living in the US have been nearly excluded from dysarthria management. Most of these are first-generation immigrants who are well documented to have limited access to financial and medical services and have poorer health outcomes including communication difficulties. This creates critical health disparities in the field of communication rehabilitation.

This study will (1) examine effects of speech therapy on PD patients' speech acoustics and intelligibility, (2) examine effects of the intervention program on communication participation and well-being of both PD patients and their families. Our primary outcome measures, speech intelligibility and acoustic measures, are hypothesized to show improvements. Acoustic predictors of speech intelligibility are expected to include acoustic vowel space and voice onset time. These hypotheses are based on literature reporting (1) positive changes in speech function after intensive treatment programs focusing on vocal effort and hyperarticulation and (2) language-specific contributors to speech intelligibility in PD. Our secondary outcome measures include (1) communication participation and (2) well-being measures which will be obtained from both PD patients and family members. Based on previous research, the measures are hypothesized to show improved communication participation and well-being in both PD patients and their families following therapy.
This study will enroll two groups of 250 patients who are to undergo prostatic biopsy as part of their routine medical care because of suspicion of prostate cancer (elevated PSA between 2 and 10 ng/ml, abnormal rectal examination, or both). The first group will contain 250 patients of African-American descent and the second will contain 250 Caucasian men.
Early identification of resistant cancer cells is currently a major challenge, as their expansion leads to refractoriness. To capture the dynamics of these cells, we made a comprehensive analysis of disease progression and treatment response in a chronic lymphocytic leukemia (CLL) patient using a combination of single-cell and bulk genomic methods. At diagnosis, the patient presented with unfavorable genetic markers, including notch receptor 1 (NOTCH1) mutation and loss(11q). The initial and subsequent treatment lines did not lead to a durable response and the patient developed refractory disease. Refractory CLL cells featured substantial dysregulation in B-cell phenotypic markers such as human leukocyte antigen (HLA) genes, immunoglobulin (IG) genes, CD19 molecule (CD19), membrane spanning 4-domains A1 (MS4A1; previously known as CD20), CD79a molecule (CD79A) and paired box 5 (PAX5), indicating B-cell de-differentiation and disease transformation. We described the clonal evolution and characterized in detail two cell populations that emerged during the refractory disease phase, differing in the presence of high genomic complexity. In addition, we successfully tracked the cells with high genomic complexity back to the time before treatment, where they formed a rare subpopulation. We have confirmed that single-cell RNA sequencing enables the characterization of refractory cells and the monitoring of their development over time.
BACKGROUND: Extended soft tissue defects of the fingers-irrespective of their origin-are challenging to treat. In cases of missing amputates or crush injuries, the options are often limited to further amputation, ray resection, or free tissue transplantation. The SISAP-flap was developed to add an extra option to treat finger avulsion injuries or otherwise extended soft tissue finger defects.
METHODS: Cadaveric SISAP-flaps were individually dissected, tested for arterial perfusion using red ink and radiopaque dye, and transposed into artificially created same-size defects. After introducing this flap in the clinic, which was partially successful in the first patient, we modified the flap to its definite design.
RESULTS: Average cadaver flap size ranges between 11 cm and 22 cm in length, allowing dorsal wrapping of the flap over the fingertip and way back to the palmar metacarpophalangeal-joint. The flap is based on the distal web space perforator, which is commonly used by a dorsal metacarpal artery flap and supercharged using an intercompartmental, supraretinacular artery. Donor sites were closed primarily with little tension. Application of the flap in the clinic resulted in satisfactory functional and esthetic outcomes.
CONCLUSION: The SISAP-flap is a new option for the reconstruction of extended finger defects and should be added to the reconstructive surgeon's armamentarium of pedicled flaps, providing relatively short operating times and promising clinical outcomes.
The present invention provides a production method of cryptoporus fungus powder. Cryptoporus hypha is cultured for 6 to 7 days in culture medium of which the PH is 4 to 7 at the temperature of 23 to 30 DEG. The cryptoporus hypha is moved in a flask with culture solution and has shake cultivation for 5 days (the frequency is 150 to 220 rpm, and the temperature is 23 to 30 DEG). The hypha solution is moved in a seed tank with the culture fluid to be cultured for 48h by a differential pressure method (the ventilation quantity is 1: 0.2 to 1.0 (v/v) minute, the mixing speed of an impeller is 100 to 200 rpm, the jar pressure is 0.5 to 1.0 kg/cm<2>, and the temperature is from 23 to 30 DGE). The hypha solution cultured in a seeding tank is arranged in a fermented tank with the culture solution to ferment for 4 days (the ventilation quantity is 1: 0.2 to 0.6 v/v minute), the mixing speed of the impeller is 100 to 200 rpm, and the tank pressure is 0.5 to 1.0 kg/cm<2>, and the temperature is 23 to 30 DEG. The cryptoporus hubb is obtained by baking, crushing and sieving.
Participants will follow a structured program that includes exercise 3 times per week for about 30 minutes each time. The type of aerobic exercise will vary, but will primarily focus on in-class walking tutorials. Participants will work with a Personal Trainer to create their own physical activity program that will fit their needs and schedule. The Personal Trainer will supervise the participants directly for the first 6 weeks. Once participants are consistently and safely meeting their goals, their Personal Trainer will allow unsupervised exercise sessions.